Gantenerumab: A Novel Human Anti-Aβ Antibody Demonstrates Sustained Cerebral Amyloid-β Binding and Elicits Cell-Mediated Removal of Human Amyloid-β

Bohrmann, Bernd, Baumann, Karlheinz, Benz, Jörg, Gerber, Francoise, Huber, Walter, Knoflach, Frédéric, Messer, Jürg, Oroszlan, Krisztina, Rauchenberger, Robert, Richter, Wolfgang F., Rothe, Christine, Urban, Margit, Bardroff, Michael, Winter, Michael, Nordstedt, Christer, Loetscher, Hansruedi·2012·Journal of Alzheimer's Disease
DOI 10.3233/jad-2011-110977

Cited by (448)

Items 301–400 of 448

  1. Secretion of proteins and antibody fragments from transiently transfected endothelial progenitor cells
    Loreé C. Heller, Reynald Thinard, Mélanie Chevalier, Sezgi Arpag, Yu Jing, Ruth Greferath, Richard F. Heller, Claude S. Nicolau · 2020 · Journal of Cellular and Molecular Medicine
  2. Amyloid-Directed Antibodies: Past, Present, and Future
    Keith Noorda, Kevin J. Noorda, Marwan N. Sabbagh, John A. Bertelson, Jonathan Singer, Boris Decourt · 2024 · Journal of Alzheimer s Disease
  3. Gantenerumab for early Alzheimer’s disease: a systematic review and meta-analysis
    Artur Menegaz de Almeida, Marianna Gerardo Hidalgo Santos Jorge Leite, Lucca Moreira Lopes, Pedro Lucas Gomes Lima, Maria Luísa Siegloch Barros, Samuel Luca Rocha Pinheiro, Ítalo Barros Andrade, Patrícia Viana, Victória Morbach, Gabriel Marinheiro et al. · 2024 · Expert Review of Neurotherapeutics
  4. Opportunities for Conformation-Selective Antibodies in Amyloid-Related Diseases
    Marta Westwood, Alastair D. G. Lawson · 2015 · Antibodies
  5. Drug Development for Neurodegenerative Diseases
    Yoshitaka Nagai, Eiko Nakano Minakawa · 2015 · Springer eBooks
  6. Vaccines targeting the primary amino acid sequence and conformational epitope of amyloid‐β had distinct effects on neuropathology and cognitive deficits in EAE/AD mice
    Xiaolin Yu, Jie Zhu, Xiang‐meng Liu, Peng‐xin Xu, Yue Zhang, Rui‐tian Liu · 2020 · British Journal of Pharmacology
  7. Unveiling the inhibitory mechanism of peptidomimetic inhibitor against Aβ42 aggregation and protofibril disaggregation by molecular dynamics
    Rajdeep Kaur, Rajneet Kaur Saini, Pritpal Singh, Bhupesh Goyal · 2021 · Journal of Molecular Liquids
  8. Efficacy and APOE ε4-stratified risk of donanemab in Alzheimer's disease: A systematic review and meta-analysis of randomized clinical trials
    Anderson Matheus Pereira da Silva, Luciano Falcão, Filipe Virgílio Ribeiro, Isabelle Rodrigues Menezes, Marianna Gerardo Hidalgo Santos Jorge Leite, Elizabeth Farias, Maria Nascimento, Mariana Lee Han, João Paulo Mota Telles, Eryvelton de Souza Franco et al. · 2025 · Journal of Alzheimer s Disease
  9. Self-assembly of N-terminal Alzheimer’s β-amyloid and its inhibition
    Govindarajan Prasanna, Pu Jing · 2020 · Biochemical and Biophysical Research Communications
  10. Reproductive and developmental toxicology studies with gantenerumab in PS2APP transgenic mice
    Paul Barrow, Loris Villabruna, Alan M. Hoberman, Bernd Bohrmann, W. Richter, Christine Schubert · 2017 · Reproductive Toxicology
  11. Temporal Characterization of the Amyloidogenic APPswe/PS1dE9;hAPOE4 Mouse Model of Alzheimer’s Disease
    Martine B. Grenon, Maria-Tzousi Papavergi, Praveen Bathini, Martin J. Sadowski, Cynthia Ann Lemere · 2024 · International Journal of Molecular Sciences
  12. Long-Term Safety of Gantenerumab in Participants with Alzheimer’s Disease: A Phase III, Double-Blind, and Open-Label Extension Study (Marguerite RoAD)
    Anuja Neve, Bibha Das, Jakub Wojtowicz, Zhiyue Huang, Szofia Bullain, Michelle Watkin, Dominik Lott, Tobias Bittner, Paul Delmar, Gregory Klein et al. · 2024 · Journal of Alzheimer s Disease
  13. Biofluid biomarker changes following treatment with sabirnetug (ACU193) in INTERCEPT-AD, a phase 1 trial in early Alzheimer's disease
    Erika N. Cline, Daniel Antwi‐Berko, Karen L. Sundell, Elizabeth A. Johnson, Maddelyn Hyland, Hao Zhang, Hugo Vanderstichele, June M. Kaplow, Robert A. Dean, Erik Stoops et al. · 2025 · The Journal of Prevention of Alzheimer s Disease
  14. The Beneficial Effect of Enriched Environment on Pathogenesis of Alzheimer’s Disease
    Xingxing Chen, Jie Hu, Anbang Sun · 2018 · Yangtze Medicine
  15. Efficacy and safety of gantenerumab in the treatment of Alzheimer's disease: A meta-analysis of randomized controlled trials
    Milene Vitória Sampaio Sobral, Victor Gonçalves Soares, Ocílio Ribeiro Gonçalves, Victoria Städler de Abreu, Lucas Cael Azevedo Ramos Bendaham, Brenda Letícia Lopes Batista, Marco Antonnio Rocha dos Santos · 2024 · Archives of Gerontology and Geriatrics Plus
  16. Drug development in dementia
    Emma Louise Cunningham, Anthony Peter Passmore · 2013 · Maturitas
  17. Intradermal active full-length DNA Aβ42 immunization via electroporation leads to high anti-Aβ antibody levels in wild-type mice
    Roger N. Rosenberg, Min Fu, Doris Lambracht‐Washington · 2018 · Journal of Neuroimmunology
  18. Anti-pyroglutamate-3 Aβ immunotherapy engages microglia and inhibits amyloid accumulation in transgenic mouse models of Aβ amyloidosis
    Fan Liao, María Calvo-Rodríguez, Meha Chhaya, Julian P. Sefrin, Erik I. Charych, Mario Mezler, Diana Clausznitzer, Emily J. McGlame, Karen Zhao, Allison Rodgers et al. · 2025 · Acta Neuropathologica
  19. Regional effects of gantenerumab on neuroimaging biomarkers in the DIAN‐TU‐001 trial
    Austin A. McCullough, Charles D. Chen, Brian Andrew Gordon, Nelly Joseph‐Mathurin, Clifford R. Jack, Robert Koeppe, Russ C. Hornbeck, Deborah Koudelis, Nicole Sarah McKay, Diana A. Hobbs et al. · 2025 · Alzheimer s & Dementia
  20. Relationship between efficacy and preferential targeting of soluble Aβ aggregates
    Johanne M Kaplan, Ebrima Gibbs, Juliane A. Coutts, Beibei Zhao, Ian R. Mackenzie, Steven Samuel Plotkin, Neil R. Cashman · 2025 · Alzheimer s & Dementia Translational Research & Clinical Interventions
  21. Structural biology of cell surface receptors implicated in Alzheimer’s disease
    Stefan J. Hermans, Tracy L. Nero, Craig J. Morton, Jonathan H. Gooi, Gabriela A. N. Crespi, Nancy C. Hancock, Chen Gao, Kenta Ishii, Jasmina Markulić, Michael W. Parker · 2021 · Biophysical Reviews
  22. Dale Schenk One Year Anniversary: Fighting to Preserve the Memories
    Cassia Overk, Eliezer Masliah · 2018 · Journal of Alzheimer s Disease
  23. Modulating innate immune activation states impacts the efficacy of specific Aβ immunotherapy
    Yona Levites, Cory C. Funk, Xue Wang, Paramita Chakrabarty, Karen N. McFarland, Baxter Bramblett, Veronica O’Neal, Xufei Liu, Thomas B. Ladd, Max Robinson et al. · 2021 · Molecular Neurodegeneration
  24. Effects of blood-brain barrier opening using ultrasound on tauopathies: A systematic review
    Amandine Géraudie, Pierre De Rossi, Michael S. Canney, Alexandre C. Carpentier, Benoı̂t Delatour · 2025 · Journal of Controlled Release
  25. Japanese participant data from three gantenerumab trials in early Alzheimer's disease
    Takashi Asada, Angeliki Thanasopoulou, Paul Delmar, Jakub Wojtowicz, Janice Smith, Yasumasa Yoshiyama, Katsunori Yokoi, Chigusa Watanabe, Mitsuhiro Isozaki, Ryoto Ozaki et al. · 2025 · Alzheimer s & Dementia
  26. Pretargeted Immuno-PET Enables Monoclonal Antibody Imaging Beyond the Blood–Brain Barrier
    Tobias Gustavsson, Thomas Kustermann, Lars Hvass, Thomas Erik Wuensche, Anne Skovsbo Clausen, Sophie Stotz, Vladimir Shalgunov, Sara Lopes van den Broek, Gitte M. Knudsen, Blanca I. Aldana et al. · 2025 · Molecular Pharmaceutics
  27. Aducanumab binding to Aβ 1-42 fibrils alters dynamics of the N-terminal tail while preserving the fibril core
    Ravi Shankar Palani, Christopher G. Williams, Dev Thacker, Robert Silvers, Fang Qian, Paul H. Weinreb, Leonard J. Mueller, Sara Snogerup Linse, Robert G. Griffin · 2025 · Proceedings of the National Academy of Sciences
  28. Emerging Novel Therapeutic Approaches for the Treatment of Alzheimer’s Disease
    Amit Panwar, Mohd. Imran K. Khan, Rajesh Kumar, Rakesh Kumar, Santosh Kumar, Anil Kumar · 2024 · Advances in Alzheimer s Disease
  29. Biotechnologically engineered protein binders for applications in amyloid diseases
    Christian Haupt, Marcus Fändrich · 2014 · Trends in biotechnology
  30. The Ups and Downs of Amyloid in Alzheimer's
    Eric Siemers, Paul S. S. Aisen, María C. Carrillo · 2021 · The Journal of Prevention of Alzheimer s Disease
  31. Novel immunological approaches for the treatment of Alzheimer's disease.
    Priyanka Sabharwal, Thomas Wısnıewskı · 2014 · PubMed
  32. Transport pathways across the blood-brain barrier for waste clearance and drug delivery
    Lea S. Gröbner, Claus U. Pietrzik · 2026 · Fluids and Barriers of the CNS
  33. Biologics for the management of dementia
    Akash Chaurasiya, Sumeet Katke, Kanan Panchal, Jayabalan Nirmal · 2022 · Elsevier eBooks
  34. Suppression of amyloid-β fibril growth by drug-engineered polymorph transformation
    Sima Mafimoghaddam, Yuechuan Xu, Michael B. Sherman, Elena V. Orlova, Prashant Karki, Mehmet A. Orman, Peter G. Vekilov · 2022 · Journal of Biological Chemistry
  35. A new class of monoclonal Aβ antibodies selectively targets and triggers deposition of Aβ protofibrils
    Shikha Grover, Thao Pham, Anna Jones, Cristina Sinobas Pereira, Marina Villoch Diaz Maurino, Evan C. Garrad, Nyasha J. Makoni, Antanisha Parks, Ryan J. Domalewski, Gabriel Riggio et al. · 2023 · Journal of Neurochemistry
  36. At-home Administration of Gantenerumab by Care Partners to People with Early Alzheimer's Disease: Feasibility, Safety and Pharmacodynamic Impact
    Frank Boess, Marzia A. Scelsi, Timo Grimmer, Richard J. Perry, Mattéo Tonietto, Gregory Klein, Carsten Hofmann, M. Salami, Jeremy M. Wojtowicz, Claire J. Lansdall et al. · 2024 · The Journal of Prevention of Alzheimer s Disease
  37. Anti-Amyloid Imaging Abnormality in the Era of Anti-Amyloid Beta Monoclonal Antibodies: Recent Updates for the Radiologist
    So Yeong Jeong, Chong Hyun Suh, Jae‐Sung Lim, Yangsean Choi, Ho Sung Kim, Sang Joon Kim, Jae‐Hong Lee · 2025 · Journal of the Korean Society of Radiology
  38. Passive Immunotherapy in Alzheimer’s Disease
    Philip J. Dolan, Wagner M. Zago · 2018 · InTech eBooks
  39. Prospects and Challenges for Alzheimer Therapeutics
    Michael S. Wolfe · 2016 · Elsevier eBooks
  40. A coiled conformation of amyloid-β recognized by antibody C706
    A. Teplyakov, Galina Obmolova, Gary L. Gilliland · 2017 · Alzheimer s Research & Therapy
  41. Single-molecule characterisation of soluble beta-amyloid aggregate binding by Aducanumab, Lecanemab, Gantenerumab, and Donanemab
    Emre Fertan, Jeff Y. L. Lam, Giulia Albertini, Maarten Dewilde, Yunzhao Wu, Oluwatomi E. S. Akingbade, Dorothea Böken, Elizabeth A. English, Bart De Strooper, David Klenerman · 2024 · bioRxiv (Cold Spring Harbor Laboratory)
  42. Aducanumab binds high molecular weight soluble Aβ oligomers and restores intracellular calcium levels
    Lu Yu, Xueying Wang, Tri Huu Doan, Yutian Fan, Thierry Bussière, Brian J. Bacskai, Ksenia V. Kastanenka · 2025 · Alzheimer s Research & Therapy
  43. Structural and Functional Determinants of ARIA-H Risk in Anti-Amyloid Monoclonal Antibodies: A Comparative Mechanistic Framework for Alzheimer's Immunotherapy Development
    Dinghao An, Xinxin Zou, Yun Xu · 2025 · Current Neuropharmacology
  44. Combining AI design and molecular dynamics to disrupt amyloid aggregation in Alzheimer’s disease
    Ayla Esmaeilzadeh, Maryam Azimzadeh Irani, Ali Javanmard, Mahdiyeh Gharaei Khezri · 2026 · Discover Applied Sciences
  45. Identification of Chromatin Regulatory Factors Related to Immunity and Treatment of Alzheimer’s Disease
    Fengzhen Xiong, Chenglong Li, Qingbo Wang, Xin Geng, Zhengbo Yuan, Zefu Li · 2023 · Journal of Molecular Neuroscience
  46. ABTrans: A Transformer-based Model for Predicting Interaction between Anti-Aβ Antibodies and Peptides
    Yuhong Su, Xincheng Zeng, Lingfeng Zhang, Yanlin Bian, Yanjing Wang, Buyong Ma · 2024 · Interdisciplinary Sciences Computational Life Sciences
  47. Current Update on Promising New Anti-Alzheimer’s Drugs in Different Phases of Clinical Development: Where Exactly Are We Lacking?
    Pramod Kumar Sharma, Mamta Yadav, Neeraj Mehta · 2024 · Journal of the Association of Physicians of India
  48. The Use of Peptide and Protein Vectors to Cross the Blood-Brain Barrier for the Delivery of Therapeutic Concentration of Biologics
    Mei Tian, Reinhard Gabathuler · 2020 · Neuromethods
  49. Immunotherapeutics for AD: A Work in Progress
    Anuja Sharma, Jaspreet Singh Anand, Yatender Kumar · 2021 · CNS & Neurological Disorders - Drug Targets
  50. Immunotherapy: An Approach to Treat Alzheimer’s Disease and Autism Spectrum Disorder
    Farah Maarfi, Ziaul Hasan, Afreen Khanam, Arbab Husain, Mohammad Haroon Khan, Mohd Yasir Khan · 2021 · Springer eBooks
  51. A novel hybrid protein promotes Aβ clearance and reduces inflammatory response through MerTK
    Lorena Samentar, Arnold Salazar, Peipei Pan, Kayvon Etebar, Kelly Choy, Durin Uddin, Pauline Eliseeff, Adrienne Marrie Bugayong, Jose Antonio Ma. G. Garrido, Aurora Emini et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
  52. Alzheimer's Disease and Mild Cognitive Impairment
    David Thomas Jones, Marla B. Bruns, Ronald Carl Petersen · 2018 · Wiley eBooks
  53. Elucidation of Amyloid-Beta’s Gambit in Oligomerization: Truncated Aβ fragments of residues Aβ1-23, Aβ1-24 and Aβ1-25 rapidly seed to form SDS-stable, LMW Aβ oligomers that impair synaptic plasticity
    Beatriz Gil, Jamie L. Rose, Davide Demurtas, Gian‐Filippo Mancini, Jessica Sordet‐Dessimoz, Vincenzo Sorrentino, Nikita Rudinskiy, Matthew P. Frosch, Bradley T. Hyman, Marc Moniatte et al. · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
  54. Amyloid-β-regulated gene circuits for programmable Alzheimer’s disease therapy
    Madeline R. Spetz, Hyosung Kim, Alexander P Ligocki, Swathi R Shekharan, Hannah J. Brien, Daniel Chavarría, Dylan J Conger, Rebecca L. Shattuck-Brandt, Alena Shostak, Rebecca Embalabala et al. · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
  55. The aggregation of amyloid-β: from condensation, nucleation, and conformation to targeting therapy
    Bangyao Chen, Tiancheng Chen, Zhendong Sun, Lulu Liu, Yu Jia, Yipin Ji, Jinlong Wang, Feifei Sun, Yunpeng Huang · 2026 · Life Sciences
  56. Animal models for Alzheimer's disease – the industry perspective
    Christian Czech, Fiona Grueninger · 2013 · Drug Discovery Today Therapeutic Strategies
  57. Effect of CTerm of human albumin on the aggregation propensity of Aβ1-42 peptide: a potential of mean force study
    Navamallika Dutta, Priyanka Borah, Venkata Satish Kumar Mattaparthi · 2020 · Journal of Biomolecular Structure and Dynamics
  58. Recent Advances in Alzheimer’s Disease Treatments with Therapeutic Antibodies to Amyloid-β
    Jerry Yang, Aaron Bradford · 2022 · Journal of Student Research
  59. Pharmacotherapy for Alzheimer’s disease: what’s new on the horizon?
    Rita Khoury, Amy Gallop, Kelsey Roberts, Noam Grysman, Jiaxi Lu, George Thomas Grossberg · 2022 · Expert Opinion on Pharmacotherapy
  60. Compilation and Analysis of Enzymes, Engineered Antibodies, and Nanoparticles Designed to Interfere with Amyloid‐β Aggregation
    Jun Zhao, Buyong Ma, Ruth Nussinov · 2016 · Israel Journal of Chemistry
  61. Immunotherapy in Alzheimer’s Disease
    Jyoti Gupta, Mehboob Hoque · 2019 · Springer eBooks
  62. Compound Attrition in Phase II/III
    Alexander Alex, Cherell Harris, Wilma W. Keighley, Dennis A. Smith · 2015
  63. An electrostatic cluster guides Aβ40 fibril formation in cerebral amyloid angiopathy
    Elliot J. Crooks, Ziao Fu, Brandon A. Irizarry, Xiaoyue Aelita Zhu, William E. Van Nostrand, Saikat Chowdhury, Steven O. Smith · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
  64. Drug Discovery from Medicinal Plants against Alzheimer's Disease
    Mona M. Marzouk, Mai Mohammed Farid, Nesrine Mahmoud Hegazi, Shahira M. Ezzat · 2023 · Wiley eBooks
  65. Current Treatment Approaches for Alzheimer’s Disease and Possible Drug Targets
    Ashutosh Ranjan, Shashikesh Shukla, Shamsher Singh · 2024 · Current Drug Therapy
  66. Recent updates on immunotherapy in neurodegenerative diseases
    Jotiram Salunkhe, Rajesh Ramesh Ugale · 2024 · Brain Research
  67. Antibodies against Alzheimer's: Pioneering a New Era in Treatment Strategies
    Mansi Verma, Niraj Kumar Singh, Mohd Usman Mohd Siddique · 2025 · Current Bioactive Compounds
  68. Anti-amyloid antibody therapies for Alzheimer's disease: how much do we really understand?
    Yun Chen · 2026 · Targetome
  69. In vitro blood-brain barrier models for the study of brain shuttle peptide transport
    Ana Filipa Martins, Ana Raquel Santa-Maria, Nóra Kucsápszky, Luíza Santa Brígida de Barros Góes, Kinga Cserne Molnár, Sheila Sousa Gomes Fortes, Emanuel Carrilho, Mária A. Deli, Fruzsina R. Walter · 2026 · Advances in pharmacology
  70. Ouvrir le cerveau à de nouvelles thérapies
    Ludovic Collin · 2014 · médecine/sciences
  71. Immunotherapy Against Amyloid-β in Alzheimer’s Disease: An Overview
    Niels D. Prins · 2016 · Methods in pharmacology and toxicology
  72. Epitope Mapping by NMR of a Novel Anti-Aβ Antibody (STAB-MAb)
    Adrián Posado-Fernández, Cláudia F. Afonso, Gonçalo Dória, Orfeu Flores, Eurico J. Cabrita · 2019 · Scientific Reports
  73. Biosensors for detection of Alzheimer’s disease: a review
    Manju Tewari · 2024 · Elsevier eBooks
  74. Long-term safety of gantenerumab in participants with Alzheimer's disease: A phase III, open-label extension study (SCarlet RoAD)
    Merçé Boada, Anuja Neve, Bibha Das, Jakub Wojtowicz, Zhiyue Huang, Szofia Bullain, Michelle Watkin, Dominik Lott, Tobias Bittner, Paul Delmar et al. · 2024 · Journal of Alzheimer s Disease
  75. The future of dementia prevention and treatment strategies
    里 直行 · 2020 · Nippon Ronen Igakkai Zasshi Japanese Journal of Geriatrics
  76. Current and Prospective Treatments for Alzheimer's Disease (and Other Neurodegenerative Diseases)
    Steve Pedrini, Mike Morici, Ralph Nigel Martins · 2019 · Wiley eBooks
  77. An in vivo model of Amyloid-Related Imaging Abnormalities (ARIA) predicts ARIA incidence of anti-Aβ antibodies seen in clinical trials
    Edward D. Plowey, Jordan Abettan, Peter Cheng‐te Chou, Ming Lye‐Barthel, Ana Claudia Silva Amaral, Jennifer Sebalusky, Stefan Hamann, Jared Srinivasan, Roland Z. Brown, Qian Fang et al. · 2026 · bioRxiv (Cold Spring Harbor Laboratory)
  78. Early Binding of Anti-Amyloid Antibodies to CAA Drives Complement Activation, Inflammation and ARIA in Mice
    Praveen Bathini, Stephan Schilling, Jens‐Ulrich Rahfeld, David M. Holtzman, Takaomi C. Saido, Cynthia Ann Lemere · 2026 · bioRxiv (Cold Spring Harbor Laboratory)
  79. Antibodies in Phase III Studies for Immunological Disorders
    Penelope Ward, Mark Bodmer · 2014 · Wiley eBooks
  80. Brain Effect Site Pharmacokinetics: Delivery of Biologics Across the Blood–Brain Barrier
    Gert Fricker, Anne Mahringer · 2015 · Wiley eBooks
  81. AD Prevention Trial Moves Forward
    Dawn Fallik · 2012 · Neurology Today
  82. Amyloid beta 4-42 in Alzheimer’s disease: Target, Therapy, Mechanism
    Gregory Antonios · 2016 · eDiss (Georg-August-Universität Göttingen)
  83. Immunotherapeutic Approaches Against Amyloid-β in Drug Discovery for Alzheimer’s Disease
    Seung‐Hoon Yang, Jiyoon Kim, Young Soo Kim · 2015 · Springer eBooks
  84. Open questions for Alzheimer's disease
    Todd Eliot Golde · 2014
  85. Efficacy of three nonpharmacological interventions for Alzheimer's disease
    Aaron Thomas Artiles · 2016 · OpenBU (Boston University)
  86. The microrna-mediated regulation of proteins implicated in the pathogenesis of Alzheimer's Disease
    Nipun Chopra · 2016 · IUScholarWorks (Indiana University)
  87. Immunotherapy for the Treatment of Alzheimer’s Disease
    A. A. Farooqui · 2017 · Elsevier eBooks
  88. Spectrum of Pharmacological Activity of Monoclonal Antibodies
    А. V. Zaychenko, Н. А. Горчакова, O. V. Shumeiko, Olena Klymenko, O. V. Khodakivska · 2019 · Ukraïnsʹkij žurnal medicini bìologìï ta sportu
  89. Investigating the role of normal and abnormal beta-amyloid processing in cognition
    Thomas J. Freeman · 2019 · ORCA Online Research @Cardiff (Cardiff University)
  90. Genomics of Alzheimer’s disease
    Roger N. Rosenberg, Doris Lambracht‐Washington, Gang Yu, Weiming Xia · 2020 · Elsevier eBooks
  91. Exploring the Efficacy of Anti-amyloid-β Therapeutics in Treating Alzheimer Disease
    Ciara Downey · 2022 · Youth STEM Matters
  92. New therapeutic opportunities for Alzheimer disease
    Jae‐Won Jang · 2022 · Journal of Geriatric Neurology
  93. Preclinical Longitudinal In Vivo Biomarker Platform for Alzheimer’s Disease Drug Discovery
    Min Su Kang, Eduardo Rigon Zimmer, Julie Ottoy, Monica Shin, Marcel S. Woo, Arturo Aliaga, Gassan Massarweh, A. Claudio Cuello, Serge G. Gauthier, Pedro Rosa‐Neto · 2022 · Cambridge University Press eBooks
  94. Neuropharmacology in Alzheimer and Huntington Disease
    Bandna Gupta, Kopal Rohatgi · 2022 · BENTHAM SCIENCE PUBLISHERS eBooks
  95. A pipeline for facile cloning of antibody Fv domains and their expression, purification, and characterization as recombinant His-tagged IgGs
    Akesh Sinha, Jinha Mark Park, Naveed Gulzar, Darpan N. Pandya, Thaddeus J. Wadas, Jamie Kathleen Scott · 2024 · bioRxiv (Cold Spring Harbor Laboratory)
  96. Challenges and opportunities in neurometabolic disease treatment with enzyme delivery
    David J. Begley, Reinhard Gabathuler, Gregory M. Pastores, Àngels García‐Cazorla, Diego Ardigò, Maurizio Scarpa, Rosella Tomanin, Giovanni Tosi · 2024 · Expert Opinion on Drug Delivery
  97. Genomics of Alzheimer’s disease
    Roger N. Rosenberg, Doris Lambracht‐Washington, Gang Yu, Weiming Xia · 2024 · Elsevier eBooks
  98. The calcium channel blocker Cav2.1 combined with amyloid beta monoclonal antibodies may reduce the occurrence of ARIA-E
    Dinghao An, Xiaotong Li, Yang Y. Xu · 2025 · Medical Hypotheses
  99. Transferrin receptor-binding blood-brain barrier shuttle enhances brain delivery and efficacy of a therapeutic anti-Aβ antibody
    Marta Ramos Vega, Henrik H. Hansen, Camilla Stampe Jensen, Evdoxia Alexiou, Martin Rønn Madsen, Franziska Wichern, Jacob Lercke Skytte, Casper Graversen Salinas, Florence Sotty, Allan Jensen et al. · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
  100. Probing Macromolecular Interactions by Loss of Solvent Content in Protein Crystals: Application to the Amyloid-β Peptide Binding to Transthyretin
    Diogo Costa-Rodrigues, José P. Leite, Luı́s Gales · 2025 · Crystal Growth & Design